BIO Is “Cautiously Optimistic” About Post-McClellan FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Senior agency officials appear committed to outgoing commissioner’s goals, BIO policy chief Werner says.
You may also be interested in...
Genentech Expresses "Concern" About FDA Drug Approvals In McClellan’s Absence
Drug approval timelines and FDA’s "spirit of urgency" could be impacted by the commissioner’s departure for CMS.
Crawford To Head Reorganized FDA; McClellan Moves To CMS
CDER Director Woodcock becomes deputy commissioner for operations under an agency management reshuffling aimed at ensuring a smooth transition.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.